Condition-specific apps generate higher-fidelity PRO data
Patients who open an app built for their condition report more consistently than patients using a horizontal tracker. Clarity’s fleet captures condition-aligned instruments by default — a research advantage before a study even starts.
What the platform offers research teams
Custom ePRO modules
Add study-specific instruments (PROMIS, disease-specific PROs, custom scales) alongside the condition’s default bundle. Scheduled, gated, or trigger-based.
Opt-in subject recruitment
Consenting users in eligible cohorts can be offered study enrollment from inside the app. No cold outreach.
Longitudinal follow-up
Patients stay on the app long after a study window closes. Long-term follow-up ePRO is built-in.
Structured export
De-identified CSV, SAS, or FHIR export on the schedule your protocol specifies. Access revocable at any time.
Digital biomarker access
Where Apple Health and Health Connect data is consented, sleep, activity, and vitals are available as study variables.
Adherence capture
Medication, injection, and regimen adherence as primary or secondary endpoints, time-aligned to PRO.
Fit-for-purpose designs
| Study type | How Clarity helps | Typical outputs |
|---|---|---|
| Observational RWE | Consented cohort access with longitudinal ePRO, adherence, and biomarkers | De-identified dataset, analysis-ready cut |
| DCT ePRO arm | Study-specific instruments inside an existing condition app | CDISC-aligned exports, site-free recruitment |
| Digital-endpoint validation | Paired PRO and digital biomarker capture during validation window | Concurrent validity datasets |
| Post-market surveillance | Adverse event and PRO capture after launch, consented cohort | Safety-signal reports, trend dashboards |
| Instrument development | Cognitive-interview, pilot, and psychometric evaluation inside real cohorts | Item-level psychometrics |
Research consent is separate
A Clarity user agreeing to use the consumer app has not agreed to be in research. Every study has its own consent surface and IRB oversight.
IRB review
Every study requires a reviewing IRB. Clarity works with your IRB of record or recommends one.
Subject re-consent
Eligible users see a study-specific consent flow inside the app. Declining continues consumer use as normal.
Scope-limited access
Researcher access is scoped to the variables the protocol defined. Nothing broader.
De-identified by default
HIPAA Safe Harbor de-identification for all shared data unless the protocol requires identified access with explicit subject consent.
Revocable
Subjects can withdraw at any time per IRB protocol. Withdrawal is processed on the schedule the IRB approved.
Where cohort density is strongest
Cohort magnitudes are bucketed. Exact numbers shared under NDA once scope is discussed.
| Therapeutic area | Representative apps | Engaged-user magnitude |
|---|---|---|
| Metabolic / GLP-1 | Pepture, GLP-1 Tracker, Diabetes, PCOS | Tens of thousands |
| Neurology | MS, Migraine, PTSD, Lyme | Tens of thousands |
| Psychiatry | BPD, Bipolar, Anxiety, Depression, ADHD, OCD | Tens of thousands |
| Autoimmune / rheum | Hashimoto, Lupus, Arthritis, Psoriasis, Eczema | Thousands to tens of thousands |
| Women’s health | IVF, PCOS, Endometriosis | Thousands to tens of thousands |
| Cardiopulmonary | AFib, Hypertension, Asthma, COPD | Thousands |
| Oncology / chronic | Cancer, MCAS, CFS, Fibromyalgia | Thousands |
Boundaries that make research trustworthy
Separate consent
Research consent is a distinct surface from consumer or clinician-access consent. No silent upgrades.
No resale
Clarity does not sell datasets to data brokers or downstream buyers. Research access is bilateral with a named study partner.
Safe Harbor by default
HIPAA Safe Harbor de-identification applied before researcher access unless the protocol and IRB approve identified access.
Subject withdrawal
Subjects can withdraw per IRB protocol; downstream data handling follows the protocol’s withdrawal rules.
Publication rights
Researchers retain publication rights per study agreement. Clarity reviews for accuracy, not for veto.
Audit trail
Every researcher access event is logged and available to the IRB on request.
How researchers engage
| Tier | For | What you get |
|---|---|---|
| Exploratory | Feasibility, grant prep | Bucketed cohort sizes under NDA, protocol review, IRB coordination |
| Observational RWE | Peer-reviewed observational work | De-identified longitudinal dataset, analysis-ready cut, collaboration on methods |
| Instrument validation | PRO instrument developers | Paired classical and digital PRO captures, psychometric output |
| DCT ePRO arm | Sponsored clinical trials | Study-specific instruments in-app, CDISC-aligned exports, SSO for site coordinators |
| Custom | Pharma RWE / surveillance | Negotiated scope, SLA, data residency, publication rights |
Research questions
Do subjects re-consent for research use?
What is the data access model?
Can we run a DCT with Clarity as an ePRO vendor?
Who owns publications?
What is the cost model?
How long does setup take?
Tell us about your study
Brief aims, PI, institution, and IRB status. A Clarity research lead will respond within two working days.